Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13
Vaxart (NASDAQ: VXRT) has scheduled its first quarter 2025 business update and financial results conference call for May 13, 2025, at 4:30 p.m. ET, following the market close. The company's senior management team will host the conference call, which will be accessible via webcast and telephone. Investors can participate using domestic line (877) 407-0832 or international line (201) 689-8433 with Conference ID 13753354. Investors may submit questions in advance to ir@vaxart.com by May 12, 2025. A replay of the webcast will be available on Vaxart's website after the event.
Vaxart (NASDAQ: VXRT) ha programmato l'aggiornamento aziendale e la conferenza sui risultati finanziari del primo trimestre 2025 per il 13 maggio 2025, alle 16:30 ET, dopo la chiusura del mercato. Il team di alta dirigenza della società condurrà la conferenza, che sarà accessibile tramite webcast e telefono. Gli investitori possono partecipare chiamando la linea nazionale (877) 407-0832 o la linea internazionale (201) 689-8433 con ID conferenza 13753354. È possibile inviare domande in anticipo all'indirizzo ir@vaxart.com entro il 12 maggio 2025. Una registrazione del webcast sarà disponibile sul sito web di Vaxart dopo l'evento.
Vaxart (NASDAQ: VXRT) ha programado su actualización empresarial y conferencia de resultados financieros del primer trimestre de 2025 para el 13 de mayo de 2025 a las 4:30 p.m. ET, tras el cierre del mercado. El equipo directivo senior de la compañía dirigirá la llamada, que será accesible vía webcast y teléfono. Los inversores pueden participar usando la línea nacional (877) 407-0832 o la línea internacional (201) 689-8433 con ID de conferencia 13753354. Los inversores pueden enviar preguntas por adelantado a ir@vaxart.com antes del 12 de mayo de 2025. Una repetición del webcast estará disponible en el sitio web de Vaxart después del evento.
Vaxart (NASDAQ: VXRT)는 2025년 1분기 사업 업데이트 및 재무 실적 컨퍼런스 콜을 2025년 5월 13일 오후 4시 30분(동부 시간)에 시장 마감 후에 예정했습니다. 회사의 고위 경영진이 컨퍼런스 콜을 주최하며, 웹캐스트와 전화로 참여할 수 있습니다. 투자자들은 국내 전화 (877) 407-0832 또는 국제 전화 (201) 689-8433를 통해 회의 ID 13753354로 참여할 수 있습니다. 투자자들은 2025년 5월 12일까지 ir@vaxart.com으로 사전 질문을 제출할 수 있습니다. 웹캐스트 녹화는 행사 후 Vaxart 웹사이트에서 이용 가능합니다.
Vaxart (NASDAQ : VXRT) a programmé sa mise à jour commerciale et sa conférence sur les résultats financiers du premier trimestre 2025 pour le 13 mai 2025 à 16h30 ET, après la clôture du marché. L'équipe de direction de la société animera la conférence, accessible par webcast et téléphone. Les investisseurs peuvent participer en appelant la ligne nationale au (877) 407-0832 ou la ligne internationale au (201) 689-8433 avec l'ID de conférence 13753354. Les investisseurs peuvent soumettre leurs questions à l'avance à ir@vaxart.com avant le 12 mai 2025. Un replay du webcast sera disponible sur le site de Vaxart après l'événement.
Vaxart (NASDAQ: VXRT) hat seinen Geschäftsbericht und die Finanzergebnisse für das erste Quartal 2025 für den 13. Mai 2025 um 16:30 Uhr ET nach Börsenschluss angekündigt. Das Führungsteam des Unternehmens wird die Telefonkonferenz leiten, die per Webcast und Telefon zugänglich sein wird. Investoren können über die nationale Nummer (877) 407-0832 oder die internationale Nummer (201) 689-8433 mit der Konferenz-ID 13753354 teilnehmen. Fragen können Investoren bis zum 12. Mai 2025 im Voraus an ir@vaxart.com senden. Eine Aufzeichnung des Webcasts wird nach der Veranstaltung auf der Website von Vaxart verfügbar sein.
- None.
- None.
Conference call to begin at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET.
The conference call can be accessed using the following information:
Webcast: Click here
Date: Tuesday, May 13, 2025 – 4:30 p.m. ET
Domestic: (877) 407-0832
International: (201) 689-8433
Conference ID: 13753354
Investors may submit written questions in advance of the conference call to ir@vaxart.com by May 12, 2025.
A replay of the webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
Vaxart Media and Investor Relations:
Matt Steinberg
FINN Partners
IR@vaxart.com
(646) 871-8481
This press release was published by a CLEAR® Verified individual.
FAQ
When is Vaxart (VXRT) reporting Q1 2025 earnings?
How can I join Vaxart's Q1 2025 earnings call?
Can investors ask questions during Vaxart's Q1 2025 earnings call?
Will there be a replay of Vaxart's Q1 2025 earnings call?
